Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Journal of clinical pharmacology

• Publication date

  1987-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/j.1552-4604.1987.tb02191.xPMID 3680580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nalmefene: Intravenous safety and kinetics of a new opioid antagonist

  1986cited by this paper
• Prolonged blockade of opioid effect with oral nalmefene

  1986cited by this paper
• Binding of a new opiate antagonist, nalmefene, to rat brain membranes.

  1985cited by this paper
• Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.

  1984cited by this paper
• PHARMACOKINETICS OF INTRAVENOUS NALOXONE IN HEALTHY VOLUNTEERS

  1984cited by this paper
• Nalmefene: radioimmunoassay for a new opioid antagonist.

  1984cited by this paper
• Nalmefene: quantitation of a new narcotic antagonist in human plasma using high performance-liquid chromatography with electrochemical detection.

  1983cited by this paper
• Pharmacokinetic and biopharmaceutic parameters during enterohepatic circulation of drugs.

  1982cited by this paper
• Metabolism and disposition of naltrexone in man after oral and intravenous administration.

  1981cited by this paper
• Model-Independent Linear Pharmacokinetics

  1976cited by this paper
• Narcotic antagonists. 4. Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists.

  1975cited by this paper

• Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model‐Based Evaluation of Important Pharmacological Attributes

  2025cites this paper
• Reversal of subtype-selectivity and function by the introduction of a para-benzamidyl substituent to N-cyclopropylmethyl nornepenthone.

  2023cites this paper
• Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose

  2023cites this paper
• Treatment of opioid overdose: current approaches and recent advances

  2022cites this paper
• Pharmacologic and Clinical Considerations of Nalmefene, a Long Duration Opioid Antagonist, in Opioid Overdose

  2021cites this paper
• Nalmefene, a Mu Opioid Receptor Antagonist/Kappa Opioid Receptor Partial Agonist, Potentiates Cocaine Motivation But Not Intake with Extended Access Self-Administration in Adult Male Mice.

  2021cites this paper
• Predicting drug-metagenome interactions: Variation in the microbial β-glucuronidase level in the human gut metagenomes

  2021cites this paper
• GluN2A-selective positive allosteric modulator-nalmefene-flumazenil reverses ketamine-fentanyl-dexmedetomidine-induced anesthesia and analgesia in rats

  2020cites this paper
• Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression.

  2020cites this paper
• Safety of nalmefene for the treatment of alcohol use disorder: an update

  2019cites this paper
• Efficacy and Tolerability of Long-Acting Injectable Formulation of Nalmefene (Nalmefene Consta 393.1 mg) for Opioid Relapse Prevention: A Multicentre, Open-Label, Randomised Controlled Trial

  2019cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018influential citation
• Naltrexone and nalmefene attenuate cocaine place preference in male mice

  2018cites this paper
• Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017influential citation
• Nalmefene Prevents Alcohol‐Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4

  2017cites this paper
• Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.

  2016cites this paper
• Functional imaging of neural systems associated with alcohol reward and amphetamine toxicity

  2016cites this paper
• Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine.

  2016cites this paper
• Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis

  2016cites this paper
• Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus

  2016cites this paper
• Lipophilic nalmefene prodrugs to achieve a one-month sustained release.

  2016cites this paper
• Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential

  2016cites this paper
• The opioid receptors as targets for drug abuse medication

  2015cites this paper
• In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene

  2015cites this paper
• [Neurobiology of alcohol and pharmacological aspects of nalmefene].

  2015cites this paper
• Recent Developments in Pharmacotherapy of Alcoholism

  2015cites this paper
• Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats.

  2014cites this paper
• [Nalmefene: a novel pharmacotherapeutic option for alcoholism].

  2014cites this paper
• Nalmefene for the treatment of alcohol dependence: a current update.

  2014influential citation
• The role of the opioid system in alcohol dependence

  2014cites this paper
• Pharmacotherapy for alcohol dependence: status of current treatments.

  2013cites this paper
• Nalmefene: A Review of Its Use in the Treatment of Alcohol Dependence

  2013cites this paper
• Targeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders

  2013cites this paper
• Antidotes for toxicological emergencies: a practical review.

  2012cites this paper
• Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ‐Opioid Receptor Inverse Agonist

  2012cites this paper
• Pharmakotherapie der Alkoholabhängigkeit

  2011cites this paper
• Opioid modulators for alcohol dependence

  2011cites this paper
• Opioid antagonists for alcohol dependence.

  2010cites this paper
• Opioid antagonists for alcohol dependence.

  2010cites this paper
• Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.

  2010cites this paper
• Naloxone in cardiac arrest with suspected opioid overdoses.

  2010cites this paper
• Nalmefene for treatment of alcohol dependence

  2010cites this paper
• Emerging drugs to treat alcoholism

  2010cites this paper
• The Development of ProNeura Technology for the Treatment of Addictions

  2009cites this paper
• Influence of Supercritical Antisolvent Micronization Parameters on Nalmefene HCl Powder Characteristics

  2008cites this paper
• Case files of the University of Massachusetts Fellowship in Medical Toxicology: Lethal dose of opioids contained in an elastomeric capsule labeled as vancomycin

  2008cites this paper
• [Opioid antagonists and alcohol consumption].

  2007cites this paper
• Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans.

  2007cites this paper
• Imaging of opioid receptors in the central nervous system

  2007cites this paper
• Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.

  2006cites this paper
• Prolonged Central μ-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing

  2005influential citation
• Second generation opioidergic compounds: clinical data

  2005cites this paper
• Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.

  2005cites this paper
• Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.

  2004cites this paper
• Isolation of a Novel Morphinan 3-O-Diglucuronide Metabolite from Dog Urine

  2004cites this paper
• Chronic administration of nalmefene leads to increased food intake and body weight gain in mice.

  2004cites this paper
• Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry.

  2002cites this paper
• Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation.

  2002cites this paper
• Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans.

  2000influential citation
• A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.

  1999cites this paper
• Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.

  1999cites this paper
• Opioid Receptor Antagonists in Psychiatry

  1998influential citation
• Primary biliary cirrhosis

  1998cites this paper
• The pruritus of cholestasis: evolving pathogenic concepts suggest new therapeutic options.

  1998cites this paper
• Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism.

  1998cites this paper
• The pruritus of cholestasis: behavioral studies shed light on its pathogenesis

  1998cites this paper
• Nalmefene and the urine opiate screen.

  1998cites this paper
• The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.

  1998cites this paper
• Integration of research in pharmacotherapy for addictive disease: where are we? Where are we going?

  1997cites this paper
• Dosing issues in the pharmacotherapy of alcoholism.

  1996cites this paper
• Long-Term Pharmacotherapy for Opiate (Primarily Heroin) Addiction: Opioid Antagonists and Partial Agonists

  1996cites this paper
• Effects of Naloxone Infusions in Patients with the Pruritus of Cholestasis: A Double-Blind, Randomized, Controlled Trial

  1995cites this paper
• The pruritus of cholestasis.

  1995cites this paper
• Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject.

  1994cites this paper
• A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

  1994cites this paper
• Beneficial Effects of Nalmefene Augmentation in Neuroleptic-Stabilized Schizophrenic Patients

  1993cites this paper
• Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies.

  1993cites this paper
• The Pruritus of Cholestasis

  1993cites this paper
• Opiate Antagonists and Eating Behavior in Humans: A Review

  1992cites this paper
• Human pharmacology and abuse potential of nalmefene

  1991cites this paper
• Effects of nalmefene on feeding in humans

  1990cites this paper